A naukri.com initiative
Bioengineer
4d
101
Image Credit: Bioengineer
Innovative Approach for Administering Cell Therapies to Critically Ill Patients on External Lung Support
- A team in Spain has developed the Consecutive Intrabronchial Administration (CIBA) method for administering stem cell therapies to ECMO-supported critically ill patients with lung issues.
- ECMO, an advanced life support system, makes traditional intravenous cell infusions difficult, but CIBA delivers stem cells directly to the lungs without hindering ECMO function.
- The method uses bronchoscopy to target pulmonary alveoli with Wharton's jelly-derived mesenchymal stromal cells that possess regenerative and immunomodulatory properties.
- In a first case application on a critically ill child, the CIBA method was well-tolerated and led to extubation within 72 hours, showcasing its potential clinical benefits.
- The research aims to explore repeated dosing and long-term efficacy, providing a promising avenue for future clinical trials and expanded use.
- CIBA represents a fusion of pulmonology, bioengineering, and cell therapy, requiring precise control over cell delivery to avoid complications.
- By avoiding patent protection, the team intends to promote rapid adoption of CIBA in public healthcare systems globally, emphasizing equitable access to innovative treatments.
- The application of MSCs directly in the lungs postulates localized effects that can aid in mitigating lung damage and promoting tissue repair, especially in end-stage lung diseases.
- Clinical trials will be crucial to validate CIBA's effectiveness, optimize dosing, and assess safety for potential future use in adult patients and various lung conditions.
- The CIBA technique signals a shift towards integrating regenerative medicine into critical care settings, offering hope for improved outcomes in individuals facing respiratory failure.
Read Full Article
6 Likes
For uninterrupted reading, download the app